Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306904 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00306904 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 48 participants.
The verdict
NCT00306904, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF. The target population are patients with diabetic macular edema.
Interventions
- DRUG bevasiranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306904
The ClinicalTrials.gov registry entry for NCT00306904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevasiranib is the first listed.
NCT00306904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306904 about?
NCT00306904 is a clinical study titled "Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema". The purpose of this study is to evaluate the pharmacokinetics, safety and preliminary efficacy of 3 doses of Cand5. Cand5 is a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF. The target population are patients with diabetic macular edema.
What is the current status of trial NCT00306904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2006-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00306904?
The interventions under investigation include: bevasiranib (DRUG).
Who is sponsoring clinical trial NCT00306904?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.